Your browser doesn't support javascript.
loading
Risk Factors for Non-sentinel Lymph Node Metastasis in HR+/HER2- Breast Cancer With cN0.
Na, Yong Min; Park, Sang Chun; Ryu, Young Jae; Cho, Jin Seong; Park, Min Ho.
Afiliación
  • Na YM; Department of Surgery, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
  • Park SC; Department of Surgery, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
  • Ryu YJ; Department of Surgery, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
  • Cho JS; Department of Surgery, Chonnam National University Medical School & Chonnam National University Hospital, Gwang-ju, Republic of Korea.
  • Park MH; Department of Surgery, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea; mhpark@chonnam.ac.kr.
Anticancer Res ; 44(8): 3493-3500, 2024 Aug.
Article en En | MEDLINE | ID: mdl-39060066
ABSTRACT
BACKGROUND/

AIM:

This study aimed to identify the risk factors associated with non-sentinel lymph node (non-SLN) metastasis in case of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with cN0 on preoperative exam, where the sentinel lymph node (SLN) is positive. PATIENTS AND

METHODS:

We conducted a retrospective review of medical records from the Chonnam National University Hwasun Hospital, spanning from January 2013 to January 2020, focusing on patients with HR+, HER2- breast cancer. Specifically, we collected the clinical and pathological data for those patients who underwent axillary lymph node dissection (ALND) due to positive SLN.

RESULTS:

Among the 166 patients who underwent ALND after positive SLNs, median patient age was 52 years. Univariate analyses demonstrated a significant association between non-SLN metastasis and the number of positive SLNs (p=0.039), SLN positive ratio (p<0.001), and primary tumor size (p=0.018). Multivariate analysis revealed that an SLN ratio >0.55 (p=0.004, HR=3.007, 95% CI=1.427-6.335) was independently associated with non-SLN metastasis. However, neither the number of positive SLN nor primary tumor size showed associations with non-SLN metastases.

CONCLUSION:

In patients with HR+, HER2- breast cancer who are cN0, completion of ALND should be considered when the positive SLN ratio is ≥0.55. This approach aims to provide the opportunity for survival benefit through additional adjuvant therapy or to contribute to de-escalation of unnecessary surgery.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Ganglio Linfático Centinela / Metástasis Linfática Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2024 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Ganglio Linfático Centinela / Metástasis Linfática Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2024 Tipo del documento: Article Pais de publicación: Grecia